European Hematology Association: Treating Sickle Cell Disease and Beta-Thalassemia with CRISPR/Cas9 Gene Editing – PR Newswire (press release)
|
European Hematology Association: Treating Sickle Cell Disease and Beta-Thalassemia with CRISPR/Cas9 Gene Editing
PR Newswire (press release) Our approach is to use our CRISPR/Cas9 gene editing tool to re-create the small changes to the DNA that cause "Hereditary Persistence of Fetal Hemoglobin" and lead to expression of the protective fetal hemoglobin to reduce symptoms in patients with … |
